$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

$egrx Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000082787120000014 Filed on May 11, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$46.02M	$49.79M
YoY Change	-7.56%	6.78%
Cost Of Revenue	$4.765M	$9.554M
YoY Change	-50.13%	32.27%
Gross Profit	$41.26M	$36.69M
YoY Change	12.46%	5.36%
Gross Profit Margin	89.65%	73.69%
Selling, General & Admin	$24.76M	$18.14M
YoY Change	36.46%	19.4%
% of Gross Profit	60.0%	49.45%
Research & Development	$9.427M	$6.375M
YoY Change	47.87%	-63.19%
% of Gross Profit	22.85%	17.38%
Depreciation & Amortization	$251.0K	$242.0K
YoY Change	3.72%	-29.03%
% of Gross Profit	0.61%	0.66%
Operating Expenses	$34.18M	$37.62M
YoY Change	-9.13%	-15.13%
Operating Profit	$4.035M	$12.17M
YoY Change	-66.84%	427.94%
Interest Expense	$889.0K	$686.0K
YoY Change	29.59%	1.63%
% of Operating Profit	22.03%	5.64%
Other Income/Expense, Net	-$7.043M	-$192.0K
YoY Change	3568.23%	-70.37%
Pretax Income	-$3.008M	$11.98M
YoY Change	-125.11%	622.81%
Income Tax	-$137.0K	$3.004M
% Of Pretax Income		25.08%
Net Earnings	-$2.871M	$8.973M
YoY Change	-132.0%	243.0%
Net Earnings / Revenue	-6.24%	18.02%
Basic Earnings Per Share	-$0.21	$0.64
Diluted Earnings Per Share	-$0.21	$0.62
COMMON SHARES
Basic Shares Outstanding	13.67M shares	13.93M shares
Diluted Shares Outstanding	13.67M shares	14.42M shares

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$202.0M	$102.1M
YoY Change	97.85%	6.69%
Cash & Equivalents	$202.0M	$102.1M
Short-Term Investments
Other Short-Term Assets	$691.0K	$401.0K
YoY Change	72.32%	-30.86%
Inventory	$8.434M	$10.27M
Prepaid Expenses
Receivables	$54.49M	$63.93M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$275.6M	$182.2M
YoY Change	51.22%	7.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.423M	$2.333M
YoY Change	3.86%	-64.1%
Goodwill	$39.74M	$39.74M
YoY Change	0.0%	0.0%
Intangibles	$14.92M	$17.47M
YoY Change	-14.63%	-22.86%
Long-Term Investments
YoY Change
Other Assets	$15.53M	$3.565M
YoY Change	335.62%	3263.21%
Total Long-Term Assets	$86.37M	$77.22M
YoY Change	11.85%	-4.04%
TOTAL ASSETS
Total Short-Term Assets	$275.6M	$182.2M
Total Long-Term Assets	$86.37M	$77.22M
Total Assets	$361.9M	$259.5M
YoY Change	39.5%	4.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.756M	$16.79M
YoY Change	-41.88%	79.47%
Accrued Expenses	$20.12M	$22.44M
YoY Change	-10.31%	71.24%
Deferred Revenue	$6.019M
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$116.0M	$5.000M
YoY Change	2220.0%	-20.0%
Total Short-Term Liabilities	$145.9M	$44.22M
YoY Change	229.88%	53.76%
LONG-TERM LIABILITIES
Long-Term Debt	$30.78M	$37.00M
YoY Change	-16.81%	-11.11%
Other Long-Term Liabilities	$3.454M	$2.870M
YoY Change	20.35%	310.0%
Total Long-Term Liabilities	$34.24M	$39.87M
YoY Change	-14.13%	-4.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$145.9M	$44.22M
Total Long-Term Liabilities	$34.24M	$39.87M
Total Liabilities	$180.1M	$84.09M
YoY Change	114.19%	19.47%
SHAREHOLDERS EQUITY
Retained Earnings	$69.63M	$67.16M
YoY Change	3.68%	132.39%
Common Stock	$17.00K	$17.00K
YoY Change	0.0%	6.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$172.9M	$153.9M
YoY Change	12.32%	75.29%
Treasury Stock Shares	2.933M shares	2.590M shares
Shareholders Equity	$181.8M	$175.4M
YoY Change
Total Liabilities & Shareholders Equity	$361.9M	$259.5M
YoY Change	39.5%	4.07%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$2.871M	$8.973M
YoY Change	-132.0%	243.0%
Depreciation, Depletion And Amortization	$251.0K	$242.0K
YoY Change	3.72%	-29.03%
Cash From Operating Activities	$3.158M	$26.18M
YoY Change	-87.94%	432.03%
INVESTING ACTIVITIES
Capital Expenditures	$472.0K	$177.0K
YoY Change	166.67%	831.58%
Acquisitions
YoY Change
Other Investing Activities	-$17.50M
YoY Change
Cash From Investing Activities	-$17.97M	-$177.0K
YoY Change	10053.67%	831.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$999.0K	$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net	$1.000M	$2.500M
YoY Change	-60.0%
Cash From Financing Activities	$107.1M	-$2.656M
YoY Change	-4130.69%	-88.88%
NET CHANGE
Cash From Operating Activities	$3.158M	$26.18M
Cash From Investing Activities	-$17.97M	-$177.0K
Cash From Financing Activities	$107.1M	-$2.656M
Net Change In Cash	$92.24M	$23.35M
YoY Change	295.07%	-222.97%
FREE CASH FLOW
Cash From Operating Activities	$3.158M	$26.18M
Capital Expenditures	$472.0K	$177.0K
Free Cash Flow	$2.686M	$26.00M
YoY Change	-89.67%	430.48%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000827871
CY2020Q1	egrx	Securities Purchase Agreement Term SecuritiesPurchaseAgreementTerm	P3Y
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16537846	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16597814	shares
CY2019Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2020Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	2933320	shares
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2019Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	2907687	shares
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0261
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0165
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0257
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0047
CY2020Q1	dei	Entity File Number EntityFileNumber	001-36306
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	Eagle Pharmaceuticals, Inc.
CY2020Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8179278
CY2020Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	50 Tice Boulevard
CY2020Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 315
CY2020Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Woodcliff Lake
CY2020Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2020Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07677
CY2020Q1	dei	City Area Code CityAreaCode	(201)
CY2020Q1	dei	Local Phone Number LocalPhoneNumber	326-5300
CY2020Q1	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value per share
CY2020Q1	dei	Trading Symbol TradingSymbol	EGRX
CY2020Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13685118	shares
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3908000	USD
CY2020Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	14917000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	202016000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	109775000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	54491000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	48004000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	8434000	USD
CY2020Q1	us-gaap	Assets Assets	361944000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	6566000	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10631000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15104000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	275572000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	179449000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2423000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2202000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	15583000	USD
CY2019Q4	us-gaap	Assets Assets	254554000	USD
CY2020Q1	us-gaap	Goodwill Goodwill	39743000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	39743000	USD
CY2020Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	13759000	USD
CY2019Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	13669000	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	15530000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	9756000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5462000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	20123000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	28361000	USD
CY2020Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	116000000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	5000000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	145879000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	38823000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3454000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3000000	USD
CY2020Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	30781000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	33557000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	180114000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	75380000	USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	17000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	17000	USD
CY2020Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	285044000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	278518000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	69629000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	72500000	USD
CY2020Q1	us-gaap	Treasury Stock Value TreasuryStockValue	172860000	USD
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	171861000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	181830000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	179174000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	361944000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	254554000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	46020000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	49785000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4765000	USD
CY2019Q1	us-gaap	Royalty Expense RoyaltyExpense	3546000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9427000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6375000	USD
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9554000	USD
CY2020Q1	us-gaap	Royalty Expense RoyaltyExpense	3038000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	24755000	USD
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18141000	USD
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	41985000	USD
CY2019Q1	us-gaap	Costs And Expenses CostsAndExpenses	37616000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	4035000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	12169000	USD
CY2020Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	346000	USD
CY2019Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	494000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	889000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	686000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6500000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7043000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-192000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3008000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	11977000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-137000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3004000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-2871000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	8973000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.64
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.62
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13667606	shares
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13925227	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13667606	shares
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14418211	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	179174000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7472000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	330000	USD
CY2020Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1276000	USD
CY2020Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	999000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-2871000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	181830000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	160762000	USD
CY2019Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	198000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5782000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	42000	USD
CY2019Q1	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	9000	shares
CY2019Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	0	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	8973000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	175361000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-2871000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	8973000	USD
CY2020Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-90000	USD
CY2019Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-287000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	472000	USD
CY2019Q1	us-gaap	Depreciation Depreciation	503000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	666000	USD
CY2019Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	630000	USD
CY2020Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-6500000	USD
CY2019Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7472000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5782000	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	65000	USD
CY2019Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	94000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6487000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2556000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1868000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1961000	USD
CY2020Q1	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	-4473000	USD
CY2019Q1	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	-4368000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4294000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6869000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-8238000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1083000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	1230000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	263000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3158000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	26181000	USD
CY2020Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	17500000	USD
CY2019Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	472000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	177000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-17972000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-177000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	330000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	42000	USD
CY2020Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1276000	USD
CY2019Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	107055000	USD
CY2019Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	198000	USD
CY2019Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2500000	USD
CY2020Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	999000	USD
CY2020Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain reclassifications have been made to prior year amounts to conform with the current year presentation. None of the reclassifications were significant.</span></div>
CY2020Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	110000000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2020Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1000000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2656000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	92241000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	23348000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	109775000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78791000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	202016000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102139000	USD
CY2020Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	24000	USD
CY2019Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-6490000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	576000	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	625000	USD
CY2020Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	842000	USD
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2871000	USD
CY2020Q1	us-gaap	Basis Of Accounting BasisOfAccounting	Interim Condensed Consolidated Financial Statements<span style="font-family:inherit;font-size:10pt;">The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting quarterly information. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. The condensed consolidated balance sheet at December 31, 2019 was derived from audited financial statements, but certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the financial information for the interim periods reported have been made. Results of operations for the </span><span style="font-family:inherit;font-size:10pt;">three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results for the year ending December 31, </span><span style="font-size:10pt;">2020</span> or any period thereafter. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 2, 2020.
CY2020Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company’s critical accounting policies are those that are both most important to the Company’s financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. The Company anticipates that the COVID-19 pandemic may disrupt the Company’s supply chain and marketing and sales efforts for certain of its products, including BENDEKA, although the Company does not expect such disruption to be significant. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates, and any such differences may be material to the Company’s financial statements.</span></div>
CY2020Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	1113000	USD
CY2019Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	626000	USD
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3181083	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2238782	shares
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2871000	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	8973000	USD
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13667606	shares
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13925227	shares
CY2020Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2019Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	492984	shares
CY2020Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	13667606	shares
CY2019Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	14418211	shares
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.64
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.62
CY2020Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6993000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6521000	USD
CY2020Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4570000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4319000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2423000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2202000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	251000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	242000	USD
CY2020Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	5195000	USD
CY2019Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2460000	USD
CY2020Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	2486000	USD
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	3243000	USD
CY2020Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	753000	USD
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	863000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14917000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	8434000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	6566000	USD
CY2020Q1	us-gaap	Prepaid Taxes PrepaidTaxes	4778000	USD
CY2019Q4	us-gaap	Prepaid Taxes PrepaidTaxes	2462000	USD
CY2020Q1	egrx	Prepaid Fda User Fee PrepaidFDAUserFee	2080000	USD
CY2019Q4	egrx	Prepaid Fda User Fee PrepaidFDAUserFee	6345000	USD
CY2020Q1	us-gaap	Prepaid Insurance PrepaidInsurance	876000	USD
CY2019Q4	us-gaap	Prepaid Insurance PrepaidInsurance	191000	USD
CY2020Q1	egrx	Advancestocommercialmanufactures Advancestocommercialmanufactures	2206000	USD
CY2019Q4	egrx	Advancestocommercialmanufactures Advancestocommercialmanufactures	4661000	USD
CY2020Q1	us-gaap	Other Assets Current OtherAssetsCurrent	691000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1445000	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10631000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15104000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6019000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8364000	USD
CY2020Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	5459000	USD
CY2019Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	6004000	USD
CY2020Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2704000	USD
CY2019Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	8083000	USD
CY2020Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2441000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1926000	USD
CY2020Q1	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	873000	USD
CY2019Q4	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	1686000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1267000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1101000	USD
CY2020Q1	egrx	Number Of Operating Leases NumberOfOperatingLeases	2	lease
CY2020Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1360000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1197000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	20123000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	28361000	USD
CY2020Q1	egrx	Number Of Operating Leases NumberOfOperatingLeases	2	lease
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4337000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3716000	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2871000	USD
CY2020Q1	egrx	Operating Lease Rightof Use Asset Depreciation OperatingLeaseRightofUseAssetDepreciation	221000	USD
CY2019Q1	egrx	Operating Lease Rightof Use Asset Depreciation OperatingLeaseRightofUseAssetDepreciation	261000	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	286000	USD
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	287000	USD
CY2020Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	286000	USD
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	287000	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	286000	USD
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	287000	USD
CY2020Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y8M12D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y
CY2019Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M18D
CY2020Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.065
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06
CY2019Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.064
CY2020Q1	egrx	Number Of Operating Leases NumberOfOperatingLeases	2	lease
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6576000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1314000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1362000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1376000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1291000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	820000	USD
CY2020Q1	egrx	Lessee Operating Lease Liability Payments Due Year Six LesseeOperatingLeaseLiabilityPaymentsDueYearSix	413000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2019	egrx	Number Of Operating Leases NumberOfOperatingLeases	2	lease
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6607000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1345000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1362000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1376000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1291000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	820000	USD
CY2019Q4	egrx	Lessee Operating Lease Liability Payments Due Year Six LesseeOperatingLeaseLiabilityPaymentsDueYearSix	413000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	23100000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8183000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14917000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	23100000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7517000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	15583000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	666000	USD
CY2019Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	630000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1999000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2623000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1369000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1570000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1898000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	5458000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	172900000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2556365	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	550433	shares
CY2019Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4914	shares
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	9588	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3092296	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3096161	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	600200	shares
CY2020Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	15971	shares
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	60294	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3620096	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.5494
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.5047
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y10D
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M23D
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7472000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5782000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7472000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5782000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6576000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1314000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1362000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1376000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1291000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	820000	USD
CY2020Q1	egrx	Lessee Operating Lease Liability Payments Due Year Six LesseeOperatingLeaseLiabilityPaymentsDueYearSix	413000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2020Q1	us-gaap	Long Term Debt LongTermDebt	148000000	USD
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	114000000	USD
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	8000000	USD
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	26000000	USD
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0	USD
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	0	USD
CY2020Q1	egrx	Longterm Debt Maturities Repaymentsof Principalin Year Six LongtermDebtMaturitiesRepaymentsofPrincipalinYearSix	0	USD
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	0	USD
CY2020Q1	us-gaap	Purchase Obligation PurchaseObligation	21033000	USD
CY2020Q1	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	21033000	USD
CY2020Q1	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	0	USD
CY2020Q1	us-gaap	Purchase Obligation Due In Fifth Year PurchaseObligationDueInFifthYear	0	USD
CY2020Q1	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	0	USD
CY2020Q1	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	0	USD
CY2020Q1	egrx	Purchase Obligation Duein Sixth Year PurchaseObligationDueinSixthYear	0	USD
CY2020Q1	us-gaap	Purchase Obligation Due After Fifth Year PurchaseObligationDueAfterFifthYear	0	USD
CY2020Q1	egrx	Obligations Future Payments ObligationsFuturePayments	175609000	USD
CY2020Q1	egrx	Obligations Future Payments Due Remainder Of Fiscal Year ObligationsFuturePaymentsDueRemainderOfFiscalYear	136347000	USD
CY2020Q1	egrx	Obligations Future Payments Due In Second Year ObligationsFuturePaymentsDueInSecondYear	9362000	USD
CY2020Q1	egrx	Obligations Future Payments Due In Third Year ObligationsFuturePaymentsDueInThirdYear	27376000	USD
CY2020Q1	egrx	Obligations Future Payments Due In Fourth Year ObligationsFuturePaymentsDueInFourthYear	1291000	USD
CY2020Q1	egrx	Obligations Future Payments Due In Fifth Year ObligationsFuturePaymentsDueInFifthYear	820000	USD
CY2020Q1	egrx	Obligations Future Payments Due In Sixth Year ObligationsFuturePaymentsDueInSixthYear	413000	USD
CY2020Q1	egrx	Obligations Future Payments Due Thereafter ObligationsFuturePaymentsDueThereafter	0	USD
CY2020Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	286000	USD
CY2019Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	287000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6576000	USD
CY2020Q1	us-gaap	Purchase Obligation PurchaseObligation	21033000	USD
CY2020Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	116000000.0	USD
CY2020Q1	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	1200000	USD
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	114000000	USD
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	8000000	USD
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	26000000	USD
CY2020Q1	us-gaap	Long Term Debt LongTermDebt	148000000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-137000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3004000	USD
CY2020Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.05
CY2019Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.25
CY2020Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD

Files In Submission

Name	View Source	Status
0000827871-20-000014-index-headers.html	Edgar Link	pending
0000827871-20-000014-index.html	Edgar Link	pending
0000827871-20-000014.txt	Edgar Link	pending
0000827871-20-000014-xbrl.zip	Edgar Link	pending
egrx-20200331.xsd	Edgar Link	pending
egrx-20200331_cal.xml	Edgar Link	unprocessable
egrx-20200331_def.xml	Edgar Link	unprocessable
egrx-20200331_lab.xml	Edgar Link	unprocessable
egrx-20200331_pre.xml	Edgar Link	unprocessable
egrxq120202.htm	Edgar Link	pending
egrxq120202_htm.xml	Edgar Link	completed
exhibit102tyme-eagleco.htm	Edgar Link	pending
exhibit10tymeeaglecop_image1.gif	Edgar Link	pending
exhibit10tymeeaglecop_image2.gif	Edgar Link	pending
exhibit311q120202.htm	Edgar Link	pending
exhibit312q120202.htm	Edgar Link	pending
exhibit321q120202.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

2020 Q1 Form 10-Q Financial Statement

#000082787120000014 Filed on May 11, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX EAGLE PHARMACEUTICALS, INC. Stock $egrx

2020 Q1 Form 10-Q Financial Statement

#000082787120000014 Filed on May 11, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx